1. Meerman L. Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol. 2000; 232(Suppl):79-83.
2.
2. Schneider-Yin X, Gouya L, Meier-Weinand A, et al. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr2000; 159: 719-725.
3.
3. Varma S, Haworth A, Keefe M, et al. Delayed onset of cutaneous symptoms in erythropoietic protoporphyria. Br J Dermatol. 2000;143:221-222.
4.
4. Sonmez A, Bulucu F, Sener O, et al. Erythropoietic protoporphyria with antinuclear antibody positivity: avoiding misdiagnosis of systemic lupus erythematosus. Invest Allergol Clin, Immunol. 2000;10:47-48.
5.
5. Anstey AV. Systemic photoprotection with alpha-tocopherol (vitamin E) and beta-carotene. Clin Exper Dermatol. 2002;27: 170-176.
6.
6. Lim HW, Cohen JL. The cutaneous porphyrias. Semin Cutaneous Med Surg. 1999; 18:285-292.
7.
7. Mascaro JM. Porphyrias in Children. Pediatr Dermatol. 1992;9:371-372.
8.
8. Mathews-Roth MM, Rosner B. Long-term treatment of erythropoietic protoporphyria with cysteine. Photodermatol Photoimmunol Photomed. 2002;18: 307-309.
9.
9. Gross U, Hoffman GF, Doss MO. Erythropoietic and hepatic porphyria. JInherit Metab Dis. 2000;23:641-661.
10.
10. Sarkany RPE. Erythropoietic protoporphyria (EPP) at 40. Where are we now?Photodermatol Photoimmunot Photomed. 2002;18:147-151.
